Ultra-Rare Mutation in Long-Range Enhancer Predisposes to Thyroid Carcinoma with High Penetrance

Thyroid cancer shows high heritability but causative genes remain largely unknown. According to a common hypothesis the genetic predisposition to thyroid cancer is highly heterogeneous; being in part due to many different rare alleles. Here we used linkage analysis and targeted deep sequencing to detect a novel single-nucleotide mutation in chromosome 4q32 (4q32A>C) in a large pedigree displaying non-medullary thyroid carcinoma (NMTC). This mutation is generally ultra-rare; it was not found in 38 NMTC families, in 2676 sporadic NMTC cases or 2470 controls. The mutation is located in a long-range enhancer element whose ability to bind the transcription factors POU2F and YY1 is significantly impaired, with decreased activity in the presence of the C- allele compared with the wild type A-allele. An enhancer RNA (eRNA) is transcribed in thyroid tissue from this region and is greatly downregulated in NMTC tumors. We suggest that this is an example of an ultra-rare mutation predisposing to thyroid cancer with high penetrance.

[1]  Swneke D. Bailey,et al.  Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus , 2012, Genome research.

[2]  M. Ekker,et al.  Regulatory variations in the era of next‐generation sequencing: Implications for clinical molecular diagnostics , 2012, Human mutation.

[3]  Wei Li,et al.  The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type , 2012, Proceedings of the National Academy of Sciences.

[4]  Jason H. Moore,et al.  Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer , 2012, Science.

[5]  Q. Wei,et al.  Family history of cancer and risk of sporadic differentiated thyroid carcinoma , 2012, Cancer.

[6]  I. Tomlinson,et al.  Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression , 2012, Nature Genetics.

[7]  Kari Stefansson,et al.  Discovery of common variants associated with low TSH levels and thyroid cancer risk , 2012, Nature Genetics.

[8]  J. Lupski,et al.  Clan Genomics and the Complex Architecture of Human Disease , 2011, Cell.

[9]  Wouter de Laat,et al.  Variegated gene expression caused by cell-specific long-range DNA interactions , 2011, Nature Cell Biology.

[10]  Kerstin B. Meyer,et al.  A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression , 2011, PLoS genetics.

[11]  S. Sell,et al.  Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders , 2011, Cell cycle.

[12]  V. Nosé Familial thyroid cancer: a review , 2011, Modern Pathology.

[13]  M. Nóbrega,et al.  An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. , 2010, Genome research.

[14]  L. Carvajal-Carmona,et al.  Challenges in the identification and use of rare disease-associated predisposition variants. , 2010, Current opinion in genetics & development.

[15]  D. Goldstein,et al.  Uncovering the roles of rare variants in common disease through whole-genome sequencing , 2010, Nature Reviews Genetics.

[16]  Ian Tomlinson,et al.  Rare genetic variants and the risk of cancer. , 2010, Current opinion in genetics & development.

[17]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[18]  Hongling Liao,et al.  Long-range enhancers on 8q24 regulate c-Myc , 2010, Proceedings of the National Academy of Sciences.

[19]  M. Guerrero,et al.  Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. , 2009, Surgery.

[20]  Amy Y. Chen,et al.  Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005 , 2009, Cancer.

[21]  K. Frazer,et al.  Common vs. rare allele hypotheses for complex diseases. , 2009, Current opinion in genetics & development.

[22]  Kari Stefansson,et al.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations , 2009, Nature Genetics.

[23]  J. Kere,et al.  A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. , 2009, Cancer research.

[24]  L. Sobrinho,et al.  Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  W. Bodmer,et al.  Common and rare variants in multifactorial susceptibility to common diseases , 2008, Nature Genetics.

[26]  S. Gruber,et al.  Genetic variation in 8q24 associated with risk of colorectal cancer , 2007, Cancer biology & therapy.

[27]  D. Evans,et al.  Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening , 2006, Journal of Medical Genetics.

[28]  Michael R. Green,et al.  Transcriptional regulatory elements in the human genome. , 2006, Annual review of genomics and human genetics.

[29]  C. Malchoff,et al.  Familial nonmedullary thyroid carcinoma. , 2006, Seminars in surgical oncology.

[30]  A. Schneider,et al.  Long-term risks for thyroid cancer and other neoplasms after exposure to radiation , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[31]  Julian C. Knight,et al.  Regulatory polymorphisms underlying complex disease traits , 2005, Journal of Molecular Medicine.

[32]  S. Finkelstein,et al.  Molecular Evidence of Anaplastic Transformation in Coexisting Well-Differentiated and Anaplastic Carcinomas of the Thyroid , 2003, The American journal of surgical pathology.

[33]  P. Chappuis,et al.  Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  D E Goldgar,et al.  Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. , 2001, American journal of human genetics.

[35]  J. Pritchard Are rare variants responsible for susceptibility to complex diseases? , 2001, American journal of human genetics.

[36]  K. Hemminki,et al.  Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families , 2001, International journal of cancer.

[37]  L. Akslen,et al.  Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  A. Arnold,et al.  Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[39]  F. Canzian,et al.  A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. , 1998, American journal of human genetics.

[40]  M. Stratton,et al.  Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. , 1997, American journal of human genetics.

[41]  J. Fagin Familial nonmedullary thyroid carcinoma--the case for genetic susceptibility. , 1997, The Journal of clinical endocrinology and metabolism.

[42]  K. C. Loh,et al.  Familial nonmedullary thyroid carcinoma: a meta-review of case series. , 1997, Thyroid : official journal of the American Thyroid Association.

[43]  C. Bingle,et al.  Oct-1 interacts with conserved motifs in the human thyroid transcription factor 1 gene minimal promoter. , 1996, The Biochemical journal.

[44]  P. Mellon,et al.  The POU homeodomain transcription factor Oct-1 is essential for activity of the gonadotropin-releasing hormone neuron-specific enhancer , 1995, Molecular and cellular biology.

[45]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[46]  Sampsa Hautaniemi,et al.  Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. , 2012, Cancer genetics.

[47]  Esko Ukkonen,et al.  Locating potential enhancer elements by comparative genomics using the EEL software , 2006, Nature Protocols.

[48]  D. Kleinjan,et al.  Long-range control of gene expression: emerging mechanisms and disruption in disease. , 2005, American journal of human genetics.

[49]  Kirby D. Johnson,et al.  Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation. , 2004, Methods in molecular biology.

[50]  S. Wiseman,et al.  Anaplastic thyroid cancer evolved from papillary carcinoma: demonstration of anaplastic transformation by means of the inter-simple sequence repeat polymerase chain reaction. , 2003, Archives of otolaryngology--head & neck surgery.

[51]  Xin Chen,et al.  TRANSFAC: an integrated system for gene expression regulation , 2000, Nucleic Acids Res..